Phase 3 Trial of High-Dose Intravenous Corticosteroids Versus Standard Care for Adults With Complicated or Fulminant Acute Myocarditis

What this Trial Is About

Researchers are evaluating the effectiveness of pulsed intravenous methylprednisolone compared to standard therapy in patients with acute myocarditis, a condition marked by inflammation and damage to heart muscle cells not caused by reduced blood flow. This phase III, international, single-blind randomized controlled trial focuses on patients with complicated or fulminant acute myocarditis who experience reduced heart function and may require intensive supportive care. The study aims to determine if early corticosteroid therapy can improve outcomes by reducing inflammation in the heart during the acute phase, which has not been tested previously despite the high risks of this condition. Participants will be randomly assigned to receive either pulsed corticosteroid therapy with methylprednisolone 1 gram intravenously once daily for three days alongside standard maximal supportive care or a placebo saline solution intravenously once daily for three days plus standard care. The study includes a single-blind design and plans to recruit 360 patients, with treatments initiated within 120 hours of hospital admission. Follow-up and analysis will focus on comparing the impact of these treatments on survival and heart function over six months. During the trial, participants will undergo assessments including echocardiograms, cardiac magnetic resonance imaging, blood tests for heart injury markers, and monitoring of heart rhythms. Researchers will track major events such as death, need for heart transplant or mechanical support, arrhythmias, and hospital readmissions related to heart failure or abnormal heart rhythms. The study will also monitor safety outcomes and collect data for up to six months after treatment to evaluate the treatments effects and gather long-term information on heart recovery and patient health.

MYTHS - MYocarditis THerapy With Steroids